Actively Recruiting
Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
Led by CHU de Quebec-Universite Laval · Updated on 2024-08-22
66
Participants Needed
1
Research Sites
90 weeks
Total Duration
On this page
Sponsors
C
CHU de Quebec-Universite Laval
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this randomized controlled pilot study is to assess the feasibility, acceptability, and preliminary effects of the PACHA program designed for women having an adjuvant endocrine therapy (AET) after hormone-sensitive breast cancer. PACHA (programme en Pharmacie pour l'ACcompagnement des femmes ayant de l'Hormonothérapie Adjuvante) is a community pharmacy-based program aimed at optimizing the experience of AET and its use. The main questions it aims to answer are : * Does the program have an effect on factors expected to influence AET adherence? * Is the program acceptable? * Is the implementation of the program feasible? * What is the feasibility of procedures for carrying out a full-scale study? Participating community pharmacies will be randomized. Pharmacists working in pharmacies assigned to the PACHA group (33 pharmacies) will receive web-based training and manuals to use during their consultations with women having an AET. Recruited women attending these pharmacies will also have access to information and resources about AET (videos, evidence-based booklet). Pharmacists practicing in pharmacies assigned to the control group (33 pharmacies) will provide usual care.
CONDITIONS
Official Title
Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pharmacy is located in the province of Quebec, Canada
- At least one pharmacist agrees to manage the project in the pharmacy
- At least one woman has started adjuvant endocrine therapy (AET) in the last 6 months at the pharmacy
- Pharmacist practices in a Quebec pharmacy
- Pharmacist provides consent to participate
- Women are 18 years or older
- Women diagnosed with first non-metastatic, hormone-sensitive breast cancer
- Women received AET prescription for the first time within last 6 months
- Women are fluent in French
- Women have internet access
- Women provide consent to participate
You will not qualify if you...
- Women living in residential facilities where AET medication is not self-managed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre de recherche du CHU de Québec
Québec, Quebec, Canada, G1S 4L8
Actively Recruiting
Research Team
S
Sophie Lauzier, Ph.D.
CONTACT
J
Julie Lapointe, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here